Global Stem Cells Group and Kimera Research Labs have announced an alliance to conduct scientific research on highly manipulated cells and culture expansion, and cryopreservation of autologous stem cells.
MIAMI, April 26, 2016–Global Stem Cells Group and Kimera Research Labs have announced an alliance to conduct 
scientific research on highly manipulated stem cells and culture expansion, and cryopreservation of autologous stem cells. The collaboration will open new opportunities for GSCG to increase its participation in scientific research and development of new stem cell protocols and treatments for a number of conditions.
The manipulation of stem cells involves the ability to deliver molecules into adherent cells without disrupting differentiation, a process biotechnology researchers need in order to advance both fundamental knowledge and the state-of-the-art in stem cell research. Differentiation is the process by which an unspecialized cell, such as a stem cell, becomes specialized into one of the many cells in the body. During differentiation, certain genes become activated and other genes become inactivated in an painstakingly regulated manner. As a result, a differentiated cell develops specific structures and performs certain functions that ultimately allows it to replace damaged or dead cells. In the laboratory, a stem cell can be manipulated to become specialized or partially specialized cell types, such as heart muscle, nerve, or pancreatic cells.
“Non-destructive manipulation of stem cells in the correct environment is key to enabling technology needed within the biology and medical research communities,” says Benito Novas, CEO of Global Stem Cells Group. “To realize the promise of stem cell-based therapies to treat injuries and diseases, scientists must be able to manipulate stem cells so that they possess the necessary characteristics for successful differentiation, transplantation, and engraftment.”
To bring successful new treatments to the clinic, scientists need to control certain steps for stem cells to be useful for transplant purposes. Researchers are constantly discovering new ways to manipulate stem cells to be reproducibly made to:
- Replicate extensively and generate sufficient quantities of cells for making tissue.
- Differentiate into the desired cell type(s).
- Survive in the recipient after transplant.
- Integrate into the surrounding tissue after transplant.
- Function appropriately for the duration of the recipient’s life.
- Avoid harming the recipient in any way.
Scientists are also experimenting with different research strategies to generate tissue without the concern of immune rejection.
Research on cryopreservation of autologous stem cells is necessary for cell bank procedures in which stem cell expansion and use are not immediately needed. Cryopreservation allows for the long-term storage of hematopoietic stem cells (HSCs) and is the preferred storage technique for virtually all components intended for autologous HSC transplantation.
Cryopreservation allows the administration of multiple-day transplant conditioning regimens as well as elective storage for patients to receive transplants at a subsequent point in a course of treatment, and offers patients the opportunity to benefit from multidose protocols.
Global Stem Cells Group and Kimera Labs share a commitment to research, develop and provide stem cell treatments to patients worldwide in a clinical setting.
To learn more, visit the Global Stem Cells Group website, email bnovas(at)stemcellsgroup(dot)com, or call +1 305 560 5337.
About Global Stem Cell Group:
Global Stem Cells Group, Inc. is the parent company of six wholly owned operating companies dedicated entirely to stem cell research, training, products and solutions. Founded in 2012, the company combines dedicated researchers, physician and patient educators and solution providers with the shared goal of meeting the growing worldwide need for leading edge stem cell treatments and solutions. With a singular focus on this exciting new area of medical research, Global Stem Cells Group and its subsidiaries are uniquely positioned to become global leaders in cellular medicine.
Global Stem Cells Group’s corporate mission is to make the promise of stem cell medicine a reality for patients around the world. With each of GSCG’s six operating companies focused on a separate research-based mission, the result is a global network of state-of-the-art stem cell treatments.
About Kimera Labs:
Kimera Labs is currently focused on the use of mesenchymal stem cells (MSCs) for the suppression of various immune mediated pathologies and regenerative medicine in the US, Latin America, and the Bahamas. Founder Duncan Ross, Ph.D., is an immunologist and researcher who has studied hematopoietic stem cell transplantation for hematologic disorders, the suppression of graft vs. host disease, and various methods of immune suppression.
Kimera Labs provides patients access to stem cell treatment in the U.S. according to U.S. laws. In order to provide the greatest benefit to patients, Ross frequently travels to treat patients in Central and South America where specialists are available in a different regulatory environment.
###
To view this press release live on line, click here
